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Introduction {#sec001}
============

L1 (LINE-1) retrotransposons are genomic parasites of ancient lineage \[[@pgen.1008991.ref001]\] and have remained active in most mammals over the last 80--120 Myr. L1 replicates by copying its RNA transcripts and those of other genes into genomic DNA and by now L1 activity has generated ∼40% of the human genome \[[@pgen.1008991.ref002]--[@pgen.1008991.ref010]\]. Individual L1 families can contain thousands of copies, although most are 5'-truncated and otherwise defective on insertion. Despite their potential for seriously deleterious effects \[[@pgen.1008991.ref011]--[@pgen.1008991.ref013]\], being subject to strong negative selection \[[@pgen.1008991.ref014]--[@pgen.1008991.ref016]\] and susceptible to host repressive mechanisms \[reviewed in [@pgen.1008991.ref017]\], L1 is now the dominant active retrotransposon in many mammals, including humans, represented by the active L1Pa1 (L1Hs) family. The human genome retains a trove of L1 fossils, the relics of a series of extinct L1 families that were at one time ascendant in the primate lineage, which provide a historical record of the evolutionary antecedents of L1Pa1.

Accounting for the persistence of L1 remains a major issue for mammalian biology. Foundational, pre-whole genome studies in rodents and primates showed that evolutionary change of the 5' UTR regulatory region or the amino (N)-terminal half of ORF1p \[[@pgen.1008991.ref018]--[@pgen.1008991.ref020]\] and \[reviewed in [@pgen.1008991.ref021]\] was often associated with the emergence of novel L1 families. These studies and subsequent bioinformatic analyses showed that competition for limiting host factors or bypassing host repression likely drives the recruitment of novel 5' UTRs \[[@pgen.1008991.ref007], [@pgen.1008991.ref022]--[@pgen.1008991.ref024]\], also see \[[@pgen.1008991.ref017]\]

In contrast, the basis of variability of the N-terminal half of ORF1p is unknown. This region is dominated by an evolutionary labile coiled coil domain, a predicted motif in all vertebrate L1 families \[[@pgen.1008991.ref001]\], which contrasts with a highly conserved carboxy (C)-terminal half that mediates properties associated with retrotransposition: high affinity nucleic acid binding, nucleic acid chaperone activity, and rapid formation of stable nucleoprotein complexes([Fig 1A](#pgen.1008991.g001){ref-type="fig"}, \[[@pgen.1008991.ref025], [@pgen.1008991.ref026], and references therein\]). Coiled coil variation can occur by different means: In mice and rats by addition or deletion of heptad repeats \[[@pgen.1008991.ref018]--[@pgen.1008991.ref020], [@pgen.1008991.ref023]\]; in primates, by episodes of extensive amino acid substitutions with a signature of positive selection (more amino acid substitutions than expected by chance) \[[@pgen.1008991.ref007], [@pgen.1008991.ref027]\]. This last occurred 30--10 MYA during evolution of the primate L1Pa7-L1Pa3 families \[[@pgen.1008991.ref007], [@pgen.1008991.ref027]\]. In both mice and human, instances of coiled coil variation have been interpreted as an adaptive response to genetic changes extrinsic to ORF1p \[[@pgen.1008991.ref023], [@pgen.1008991.ref027]\].

![Retrotransposition of ORF1p variants.\
**A**---Generic L1 retrotransposon \[[@pgen.1008991.ref001], [@pgen.1008991.ref043]\]: 5' UTR (untranslated regulatory region); ORF1 (open reading frame1) with coiled coil domain (CC), which mediates trimerization of ORF1p necessary for high affinity nucleic acid binding and chaperone activity \[[@pgen.1008991.ref040], [@pgen.1008991.ref044]--[@pgen.1008991.ref046]\]; ORF2, encodes the L1 replicase with endonuclease (EN) and reverse transcriptase (RT) domains; 3' UTR with a conserved G-tetraplex forming domain (G) \[[@pgen.1008991.ref047], [@pgen.1008991.ref048]\] and an A-rich tail (A). P, location of conserved phosphorylation sites in mammalian ORF1p required for retrotransposition \[[@pgen.1008991.ref001], [@pgen.1008991.ref049]\]. NTD, RRM, CTD, N-terminal domain, RNA recognition motif, C-terminal domain, respectively. Also depicted are schematics of 8 ORF1p sequences 7 of which are mosaic structures consisting of the indicated regions of a modern active L1Pa1 (L1Hs) ORF1p (white, 111) and a resuscitated ancestral L1Pa5 ORF1p (black, 555) \[[@pgen.1008991.ref026]\]. The names of the variants are given on the right and the white numbers indicate their amino acid differences. **B**---Alignment of the N-terminal 23 amino acids and the entire 14 heptad coiled domain (alternating green and yellow boxes). Note, the heptads are numbered from 1--14 (only 8 & 9 are indicated) so as to be congruent with amino-carboxy orientation of the protein. L1Pa1 ORF1p is the reference sequence and dots and letters indicate respectively identities and differences between it and the other variants. Four columns are listed on the left: Numbers, corresponding to the subset of the variants shown in [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"} that were mapped on the coiled coil sequence space shown in [Fig 2](#pgen.1008991.g002){ref-type="fig"}; [pro exp]{.ul}---green dots, variants tested for [pro]{.ul}tein [exp]{.ul}ression in HeLa cells. Both active and inactive protein were expressed ([S1 Fig](#pgen.1008991.s001){ref-type="supplementary-material"}); [% ret]{.ul}---% retrotransposition activity in HeLa cells; [clone]{.ul}--variant names. The a-g heptad amino acid positions are shown for heptads 8 and 9, stm indicates the stammer in heptad 6. **C**--Box plots of retrotransposition assays of selected variants (bracketed in panel **B**) and representative stained G418 resistant foci and the numbers (n) of independent transfections (biological replicates) are indicated. Retrotransposition results of the other variants are shown in [S2 Fig](#pgen.1008991.s002){ref-type="supplementary-material"}.](pgen.1008991.g001){#pgen.1008991.g001}

However, here we present results that indicate an alternative model of coiled coil evolution at least in primates. We found that retrotransposition activity can tolerate extensive coiled coil amino acid changes. Such phenotypic indifference (termed genetic robustness) could be permissive to the accumulation of cryptic genetic changes, so called because they would be not subject to ("hidden" from) selection \[[@pgen.1008991.ref028]--[@pgen.1008991.ref034]\]. This condition could have increased coiled coil diversity (*i*.*e*., expand the coiled coil sequence space). Principal component analysis (PCA) along with cluster and phylogenetic analyses showed that this did occur and revealed that the coiled coil domains of each of the L1Pa7 through L1Pa3 families consist of three or more related, co-existing but distinct coiled coil sequences, some of which persisted in descendant L1 families. One of the three L1Pa3 coiled coil sequences survived in the active L1Pa1 family of modern humans and its immediate precursor L1Pa2 family, which remains active in chimpanzee and bonobo \[[@pgen.1008991.ref035], [@pgen.1008991.ref036]\].

Thus, evolution of the L1Pa7 --L1Pa3 coiled coils did not occur solely by stepwise progression through family-specific adaptive states as we and others originally proposed \[[@pgen.1008991.ref001], [@pgen.1008991.ref007], [@pgen.1008991.ref027]\], but by exploration of a variety of functional coiled coil sequences. This model of coiled coil evolution has dramatically different implications for host / L1 interaction than an adaptive model. Furthermore, an expanded functional sequence space of the coiled coil would favor L1 survival, by buffering coiled coil function \[[@pgen.1008991.ref037], [@pgen.1008991.ref038]\] from adventitious, retrotransposition-destroying coiled coil substitutions \[this study, and [@pgen.1008991.ref039], [@pgen.1008991.ref040]\]. Such profound epistasis is not unique to L1 ORF1p but is a feature of coiled coil genetics \[[@pgen.1008991.ref041], [@pgen.1008991.ref042]\]. What remains unanswered is what initiates an intense episode of coiled coil change during L1 evolution.

Results {#sec002}
=======

ORF1p activity can tolerate extensive coiled coil amino acid substitutions but is sensitive to single epistatic substitutions {#sec003}
-----------------------------------------------------------------------------------------------------------------------------

In order to address the functional consequences of the last episode of intensive coiled coil amino acid change that occurred 30--10 MYA we had resuscitated the ORF1 sequence of the now extinct L1Pa5 family ([Materials and methods](#sec007){ref-type="sec"}**)** and \[[@pgen.1008991.ref026]\], which had attained peak retrotransposition activity \~25 MYA. We refer to its encoded ORF1 protein as 555p, and as [Fig 1A](#pgen.1008991.g001){ref-type="fig"} shows, 30 of the 42 amino acids that distinguish 555p and its L1Pa1 encoded modern counterpart, 111p, are located in the coiled coil. [Fig 1B and 1C](#pgen.1008991.g001){ref-type="fig"} show that substituting 555p for modern 111p only modestly affected retrotransposition of the modern L1Pa1 element. Furthermore, mosaic ORF1 proteins consisting of an ancestral amino terminal half, 551p, or a coiled coil, which contains 21 of the 30 ancestral residues (511p) were similarly as active as the modern protein in supporting retrotransposition. And finally, an ORF1p in which all of the modern coiled coil amino acids were replaced by their ancestral counterparts (30 residues, variant 41b), retained about half of its retrotransposition activity.

Although 151p is inactive for retrotransposition, it is expressed in HeLa cells at levels comparable to 111p ([S1 Fig](#pgen.1008991.s001){ref-type="supplementary-material"}) and \[[@pgen.1008991.ref026]\]. Furthermore, 151p is essentially indistinguishable from 111p and 555p in trimer formation and several oligonucleotide-based assays: affinity for nucleic acids, nucleic acid chaperone activity, and stabilization of mismatched oligonucleotide duplexes \[[@pgen.1008991.ref026]\]. However, single molecule binding to long nucleic acids revealed the defect in 151p --while 111p and 555p trimers rapidly convert to stably bound oligomers after binding single stranded DNA, 151p trimers are unable to do so. We had suggested that the 151p coiled coil prevents its trimer from assuming a conformation that mediates its oligomerization on nucleic acids \[[@pgen.1008991.ref026]\].

Thus, one or more of the 9 ancestral coiled coil amino acids in 151p is negatively epistatic in the presence of modern residues in this protein. Stepwise replacement by their modern counterparts revealed that any one of the 4 ancestral residues in heptads 8 or 9 (positions 105, 107, 108, or 111) either in the presence of the 5 downstream ancestral residues in heptads 10, 12 and 13 (variants m15, m17, m18a, m9) or on their own (variants R105T, L107F, R108S, or C111F) inactivates ORF1p. In every case the single substitution essentially abolishes retrotransposition, recapitulating the phenotype of the 151p protein. The 5 ancestral residues in heptads 11, 12, and 13 do not affect ORF1p activity (variant m14, [Fig 1](#pgen.1008991.g001){ref-type="fig"}). Representative retrotransposition assays supporting these conclusions are shown in [Fig 1B](#pgen.1008991.g001){ref-type="fig"} and [S2 Fig](#pgen.1008991.s002){ref-type="supplementary-material"}. The green dots (column 2, pro exp, [Fig 1B](#pgen.1008991.g001){ref-type="fig"}) indicate the ORF1p variants that we tested for expression in HeLa cells. [S1 Fig](#pgen.1008991.s001){ref-type="supplementary-material"} shows that a lack of expression does not account for the retrotransposition null phenotype.

We then proceeded to restore retrotransposition competence to 151p by stepwise replacement of its modern residues to their ancestral counterparts. [Fig 1B](#pgen.1008991.g001){ref-type="fig"} shows that restitution of the partially ancestral 151p coiled coil to an active phenotype, variant (m39b), required 18 of 21 ancestral residues in heptads 1--8, and full activity was attained only upon insertion of the 18^th^ ancestral amino acid (I77L, red rectangle, [Fig 1B](#pgen.1008991.g001){ref-type="fig"}). Until then, the protein was essentially inactive for retrotransposition. Furthermore, L77 on its own (variant 151y) did not affect the activity of 151p; or a version of 151p that contained the 4 ancestral residues in the amino terminal domain (NTD, variant m28c); or the fully modern protein, variant 111a. Thus, the rescue of ORF1p activity by I77L depends on the coiled coil context afforded by most of the other ancestral residues, an instance of epistasis just as profound as the inactivating single substitutions in heptads 8 and 9. [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"} shows the effect on retrotransposition of all of the coiled coil substitutions that we examined.

[Fig 1](#pgen.1008991.g001){ref-type="fig"} shows that while some of the 30 substitutions that differentiate modern and ancestral coiled coils could be considered biochemically "conservative" (*i*.*e*., amino acids of similar charge, polarity, hydrophobicity, etc.) others are not. Thus, in terms of the coiled coil-endowed property that renders ORF1p active in retrotransposition, the coiled coil is "genetically robust" *i*.*e*., it can be phenotypically indifferent to a considerable degree of genetic change. Genetic robustness would be permissive to the accumulation of cryptic genetic changes---termed "evolvability" \[[@pgen.1008991.ref029]\], which are only manifested by the effect of epistatic substitutions as illustrated by the above examples. Theoretical and experimental studies indicate that sampling functional sequences that had been generated by a combination of randomly acquired cryptic and epistatic mutations provide an alternative model of evolutionary change to the stepwise traverse of different adaptive genetic states \[[@pgen.1008991.ref028]--[@pgen.1008991.ref033]\]. Therefore, we determined the coiled coil sequence space encompassed by all the members of the L1Pa7---L1Pa1 families as outlined in the next section and described in the Materials and Methods.

The coiled coil sequence space of the L1Pa7---L1Pa1 families {#sec004}
------------------------------------------------------------

We determined coiled coil sequence space by subjecting coiled coils alignments to two analytical techniques that provide graphical views of their sequence relatedness (see [Materials and methods](#sec007){ref-type="sec"}). The first, which generated a three-dimensional view of the coiled coil sequence space, was principal component analysis (PCA) of a single global alignment of the coiled coils. A unique 20-bit binary vector (one-hot encoding) was assigned to each amino acid, and each family was assigned a different color. [Fig 2A](#pgen.1008991.g002){ref-type="fig"} shows that the entire ensemble of coiled coils traverses a contiguous sequence space, each of which, with the exception of L1Pa2 and L1Pa1, is somewhat diffuse and elongated. Mapping the coiled coil variants on this space (numbered as in [Fig 1B](#pgen.1008991.g001){ref-type="fig"} and [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"}, large circles indicating active variants) graphically illustrates the conclusions that we made from [Fig 1](#pgen.1008991.g001){ref-type="fig"}: Genetic robustness---variant 3 maps well out of the sequence space but is fully active. Strong epistasis---the paired active and inactive variants (1 & 7; 16 & 17) share the same sequence space.

![Principal component analysis of the ORF1p coiled coil.\
**A**---The color code used for each family corresponds to one of the major clusters shown in [Fig 3](#pgen.1008991.g003){ref-type="fig"}. **B**---Large and small circles correspond respectively to active and inactive ORF1p variants mapped on the sequence space of the coiled coil of L1pa7-L1Pa1 and are numbered per [Fig 1](#pgen.1008991.g001){ref-type="fig"} and [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"}. Active variants (large circles) exhibited \~80--100% of L1Pa1 activity and inactive ones (small circles) \<5% of L1Pa1 activity.](pgen.1008991.g002){#pgen.1008991.g002}

We also used metric multidimensional scaling (MMDS), as implemented in the Bios2mds R package \[[@pgen.1008991.ref050]\], which we applied to the difference matrices of aligned coiled coils of each family (see [Materials and methods](#sec007){ref-type="sec"}). This method provides a two-dimensional graphical view of sequence diversity within each family. [Fig 3](#pgen.1008991.g003){ref-type="fig"} (cluster analysis, left side) shows that except for L1Pa2 and L1Pa1, K-means based clustering resolved the sequence space of the coiled coils of each L1 family into three or more clusters of varying compactness. The clusters are designated cLn.n, indicating the cluster and family numbers respectively; *e*.*g*., cL1.7 is cluster 1 of L1Pa7. In contrast to the coiled coils, there was little substructure in the sequence space of the L1Pa7 --L1Pa3 carboxy terminal half of ORF1p ([S4 Fig](#pgen.1008991.s004){ref-type="supplementary-material"}). We retrieved the sequences comprising the individual coiled coil clusters and found that the 50% consensus sequences of clusters cL3.5 and cL1.1 correspond respectively to the coiled coils of the 555p and 111p ORF1p sequences ([Fig 1](#pgen.1008991.g001){ref-type="fig"}).

![Cluster analysis of coiled coil sequence space.\
Panels A-F. Coiled coil clusters identified in L1Pa7 --L1Pa1 by the bios2mds R package \[[@pgen.1008991.ref050]\] as described in the Materials and Methods. Clusters are designated as follows: cLn.n, the cluster number followed by the family number---cL3.7 is cluster 3 of the L1Pa7 family. Panel F shows the projection of L1Pa1 (cL1.1) on the sequence space of L1Pa2 (cL1.2) and cL1.3, using the **mmds.project** function of the Bios2mds package as described in the Materials & Methods. Panels G-L show projection of L1Pa6 or L1Pa4 clusters on the coiled coil sequence space of L1Pa5. Panel I shows 3 coiled coil clusters for L1Pa5: cL1.5~mod~, cL3.5~mod~, and cL2.5~anc~, which belong to the modern and ancestral versions of L1Pa5 (see text). The 50% consensus sequence of the cL3.5 cluster corresponds to the 555 ORF1p sequence, marked with an asterisk, \*, on Figs [4](#pgen.1008991.g004){ref-type="fig"} and [5](#pgen.1008991.g005){ref-type="fig"}.](pgen.1008991.g003){#pgen.1008991.g003}

We used two methods to examine the relationship between coiled coils of different L1 families: (1) the **mmds.project** function of Bios2mds; (2) phylogenetic analysis using maximum likelihood. The first method projects the coiled coil sequences of a given cluster onto the sequence space of another cluster or family. [Fig 3G--3L](#pgen.1008991.g003){ref-type="fig"} show examples of this analysis wherein we projected the 2 largest L1Pa6 clusters or all of the L1Pa4 clusters onto the L1pa5 family ([Fig 3I](#pgen.1008991.g003){ref-type="fig"}). The L1Pa6 clusters showed varying degrees of overlap with sequence space of the ancestral (anc) cL2.5 cluster, and the L1Pa4 clusters exhibited different degrees of overlap with the sequence space of the modern (mod) L1Pa5 clusters., cL1.5 and cL3.5. The mod version of L1Pa5 ORF1p ([Fig 3I](#pgen.1008991.g003){ref-type="fig"}) and its descendant L1pa4--L1Pa1 ORF1p sequences lack a tripeptide located 2 residues upstream of the coiled coil that is present in anc L1Pa5, L1Pa6 and L1Pa7 (see [S1 Data](#pgen.1008991.s012){ref-type="supplementary-material"}/orf1_FL/l1pa5). However, the anc and mod L1Pa5 C-terminal half of ORF1p map to the same sequence space, [S4 Fig](#pgen.1008991.s004){ref-type="supplementary-material"}. Whereas multiple coiled coil clusters populate the L1Pa7 --L1Pa3 families, only one cluster populates the L1Pa2 and L1Pa1 families. The coiled coils of these families and cL1.3 map to the same sequence space ([Fig 3F](#pgen.1008991.g003){ref-type="fig"}).

[Fig 4](#pgen.1008991.g004){ref-type="fig"} shows that phylogenetic analysis of the 50% consensus sequences of the clusters (see [Materials & methods](#sec007){ref-type="sec"}) corroborated and extended the foregoing results. As expected, the coiled coil consensus sequences of cL1.3, L1Pa2 and L1Pa1 map to the same node. But unexpectedly, some ancestral coiled coil sequences persisted over several generations of L1 families--*i*.*e*., some coiled coil clusters recovered from the L1Pa7 --L1Pa3 families shared several (highly supported) nodes on the maximum likelihood tree. These are bracketed on [Fig 5](#pgen.1008991.g005){ref-type="fig"}, which shows an alignment of the consensus sequence of each cluster in reference to the most ancestral cluster, cL1.7. Therefore, coiled coil clusters present in the L1Pa7 and L1Pa6 families, were still being propagated in the ORF1p sequences of the L1Pa5 and L1Pa4 families (large grey triangle in [Fig 4](#pgen.1008991.g004){ref-type="fig"}). Thus, the coiled coil phylogeny differs markedly from that of ORF2p, which shows the typical single lineage of successive mammalian L1 families that emerged, amplified and went extinct\[[@pgen.1008991.ref001]\]. Also, note the 10-fold lower scale for the branch lengths of the ORF1p C-terminus tree. Taken together these results indicate that the ORF1p coiled coil, its C terminal half, and ORF2p are evolving under markedly different constraints ([Fig 4](#pgen.1008991.g004){ref-type="fig"}).

![Coiled coil phylogeny.\
Maximum likelihood trees of the coiled coil clusters and C-termini were built on their 50% consensus sequences with the amino acids encoded by CG-affected codons treated as missing data. Note the 10-fold lower scale of the branch lengths for the C-terminus tree. The colored circles at the tips of the coiled coil cluster tree correspond to the cluster colors in [Fig 3](#pgen.1008991.g003){ref-type="fig"}, panel A-F. The numbers at each node give its frequency as % of 1000 bootstrap replicates. The ORF2 tree was generated from amino acid consensus sequences of the human version of our previously described collection of L1Pa2 --L1Pa7 human/chimpanzee orthologues \[[@pgen.1008991.ref051]\] and the currently active human L1Pa1 family (in particular, Ta1-d 5), represented here by the L1.3 element \[[@pgen.1008991.ref052]\]. This tree is consistent with a previously described tree built from the 3' 2 kb of nucleic acid sequence which includes the 3'UTR but mostly ORF2 sequence (Figure 4A in \[[@pgen.1008991.ref007]\]).](pgen.1008991.g004){#pgen.1008991.g004}

![Coiled coil amino acid changes.\
The 50% consensus sequence of cL1.7, is at the top of the alignment and those of the other clusters given below, arranged according to their position on the phylogenetic tree ([Fig 4](#pgen.1008991.g004){ref-type="fig"}), with the ones sharing the same node bracketed. The number of sequences in each cluster is given in the right-hand column. Dots indicate amino acid identity, and letters indicate differences, capitalized upon their first appearance. The thin and heavy underlined positions of the cL1a.4 consensus indicate respectively the modern (111) residues that had already arisen in the coiled coil or first appeared here. The pink and blue columns highlight the emergence and replacement of the residues in heptads 8 and 9 that are negatively epistatic in the modern coiled coil ([Fig 1](#pgen.1008991.g001){ref-type="fig"}). The red box shows the emergence of I77, which is negatively epistatic in the ancestral context. The sequences of 111 with its differences from the active 555 and m39b variants and the inactive m39 variant are at the bottom of the alignment. [S5 Fig](#pgen.1008991.s005){ref-type="supplementary-material"} shows the CG-less (\_o) and CG-restored (rt) translation products of the coiled coil clusters consensus sequences. [S6 Fig](#pgen.1008991.s006){ref-type="supplementary-material"} shows a LOGO plot of the CG-restored translation products, and [S7](#pgen.1008991.s007){ref-type="supplementary-material"}--[S11](#pgen.1008991.s011){ref-type="supplementary-material"} Figs show various alignments of the coiled coil sequences that populate the cL1.3 (L1Pa3), L1Pa2 (cL1.2) and L1Pa1 (cL1.1) clusters (see [Discussion](#sec006){ref-type="sec"}).](pgen.1008991.g005){#pgen.1008991.g005}

Relationship between the effects of experimentally introduced coiled coil substitutions and the record of evolutionary change in the coiled coil clusters {#sec005}
---------------------------------------------------------------------------------------------------------------------------------------------------------

[Fig 1](#pgen.1008991.g001){ref-type="fig"} and [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"} show that each of four ancestral amino acids (T105, F107, S108, and F111) were negatively epistatic in an otherwise modern coiled coil. Furthermore, as mentioned earlier, step wise restitution of ancestral residues in the presence of this ancestral quartet (151p) had no effect until the 18^th^ (I77L) of the 21 ancestral coiled coil amino acids (that separate inactive 151p and fully active 511p) was introduced, and it completely restored activity. The alignment of the coiled coil cluster consensus sequences in [Fig 5](#pgen.1008991.g005){ref-type="fig"} shows that the ancestral quartet was present in L1Pa6 and older families (purple vertical bars). They were replaced by their modern counterparts (blue vertical bars) at about the same time and roughly coincident with the emergence of cL1a.4. By this time most of the modern residues were either already present (underlined) or coincident with their appearance in cL1a.4 (heavy underline). Furthermore, the replacement of L77 by I, which is strongly negatively epistatic in an ancestral context ([Fig 1](#pgen.1008991.g001){ref-type="fig"}, m39 *vs* m39b), was also approximately coincident with the above substitutions (*cf*. red and blue columns in [Fig 5](#pgen.1008991.g005){ref-type="fig"}). These sequence changes approximately correspond to the sharp inflection in the direction of the sequence space (arrow, [Fig 2](#pgen.1008991.g002){ref-type="fig"}) that occurred in the evolutionary path to L1Pa2 and L1Pa1. Thus, the experimentally introduced substitutions, which were carried out before, and thus without regard to the evolutionary analysis, in effect recapitulates its end result if not its chronology.

Discussion {#sec006}
==========

We demonstrated the relative indifference of L1 retrotransposition activity to extensive amino acid substitutions in the ORF1p coiled coil ([Fig 1](#pgen.1008991.g001){ref-type="fig"}, [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"}). Earlier studies showed that such lack of phenotypic effect (genetic robustness) could increase genetic diversity, which could be both revealed by, and buffer the effect of, epistatic mutations \[[@pgen.1008991.ref028]--[@pgen.1008991.ref034]\]. We found that such phenomena were associated with the episode of intense coiled coil change during the evolution of the L1Pa7-L1Pa3 families. In particular, the results in Figs [2](#pgen.1008991.g002){ref-type="fig"}--[5](#pgen.1008991.g005){ref-type="fig"} show that the expanded coiled coil sequence space could benefit L1 survival \[[@pgen.1008991.ref037], [@pgen.1008991.ref038]\] by buffering ORF1 function from adventitious, retrotransposition-destroying coiled coil substitutions \[this study, and [@pgen.1008991.ref039], [@pgen.1008991.ref040]\]. Such events are not just theoretical possibilities based on instances of epistasis exhibited by other coiled coils. [Fig 1B](#pgen.1008991.g001){ref-type="fig"} shows strong epistatic effects of single amino acid substitutions that either completely inactivated or fully revived retrotransposition. Taken together our results provide a mechanistic explanation for the instance of rampant coiled coil amino acid substitutions that occurred during the evolution of the L1Pa7 --L1Pa3 families.

The coiled coil mediates trimerization of ORF1p monomers, and the trimer is the active form of the protein in retrotransposition. Only trimers exhibit high affinity nucleic acid binding and nucleic acid chaperone activity, and ORF1p that lacks either property cannot support retrotransposition\[[@pgen.1008991.ref040], [@pgen.1008991.ref044]--[@pgen.1008991.ref046]\]. However, trimer formation *per se* is not sufficient. The 151p trimer is essentially indistinguishable from the 111p trimer by both biophysical parameters \[[@pgen.1008991.ref053]\] and nucleic acid binding and chaperone activity using oligonucleotide-based assays \[[@pgen.1008991.ref026]\], but it is inactive for retrotransposition. Therefore, a "generic" trimer is not sufficient; it also has to license the inter-trimer contacts between the C-terminal half of the protein that supports their rapid polymerization on single-stranded nucleic acid \[[@pgen.1008991.ref026]\].

Figs [2](#pgen.1008991.g002){ref-type="fig"} and [3](#pgen.1008991.g003){ref-type="fig"} indicate that each of the five families that emerged and went extinct during evolution of L1Pa7-L1Pa3 propagated related but distinct coiled coils. So, had the different coiled coil sequences amplified concurrently or sequentially during the life of the family? The persistence of coiled coil clusters 2.7, 2.6, 1.5 and 3.4 through 4 generations of L1 families (Figs [4](#pgen.1008991.g004){ref-type="fig"} and [5](#pgen.1008991.g005){ref-type="fig"}) suggest they amplified concurrently and that coiled coils maintained their identity in the presence of co-existing coiled coils.

This finding poses several issues: If hybrid trimers (*i*.*e*., those composed of monomers from different L1 clusters) can form, they would have to produce replication competent ORF1p in order to be propagated. The possibility of forming hybrid trimers could be addressed by co-expressing differentially tagged coiled coil sequences. On the other hand, hybrid trimer formation would not be an issue if L1 protein synthesis is functionally compartmentalized, which is implied by the concept of *cis* preference, whereby retrotransposition-competent L1 proteins bind to their encoding transcript. This phenomenon has been fairly well established both theoretically and experimentally for transposable elements (and some viruses) including L1 \[see [@pgen.1008991.ref054], and references [@pgen.1008991.ref013]--[@pgen.1008991.ref016] therein\]. How cis preference is mediated is unknown, but there is evidence that translation can be sequestered in subcellular compartments or translation factories \[e.g., [@pgen.1008991.ref055]\].

A second, and puzzling issue is the apparent episodic nature of coiled coil variation (see [Introduction](#sec001){ref-type="sec"}). Presumably, when a more fit coiled coil emerges, L1 elements harboring it can out compete coexisting L1 elements, which at times can mark a change in the path of the coiled coil sequence space (*e*.*g*., arrow in [Fig 2](#pgen.1008991.g002){ref-type="fig"}). Thus, the current lull in coiled coil variation may merely reflect the fact that insufficient time has elapsed for novel coiled coils to be visible above the background of existing coiled coils. The emergence of a novel coiled cluster is exemplified by cluster 1 of L1Pa3 (cLs1.3). This coiled coil and those of the L1Pa2, and L1Pa1 families have identical consensus sequences ([Fig 5](#pgen.1008991.g005){ref-type="fig"} and [S5 Fig](#pgen.1008991.s005){ref-type="supplementary-material"}). To determine whether the coiled coils of cLs1.3, L1Pa2 and L1Pa1 are undergoing differentiation we used two methods that are more sensitive than PCA determined by one-hot encoding or MMDS. These are phylogenetic analysis \[maximum likelihood [@pgen.1008991.ref056]\] and the cluster_fast command of the usearch V11 suite \[[@pgen.1008991.ref057]\]. Setting the id (identity) parameter of the cluster_fast command to 1.00 would recover coiled coil clusters that are minimally divergent from their consensus. Neither method revealed distinct clades within these coiled coils. However, sequence alignments showed that the non-CG encoded F (phenylalanine) at position 134 is hypervariable in about 10% of L1Pa2 family, generating mostly substitutions to valine (V) or serine (S) due to single nucleotide transitions or transversions in the F codons (TTT or TTC). Such variants were relatively rare in the descendant L1Pa1 family, indicating that they were not propagated or retained. These alignments are shown in [S7](#pgen.1008991.s007){ref-type="supplementary-material"}--[S11](#pgen.1008991.s011){ref-type="supplementary-material"} Figs.

In conclusion, evolution of primate ORF1 coiled coils was subject to countervailing but ultimately complementary genetic events that could result from its genetic robustness; permissiveness to enlarging the coiled coil sequence space, which in turn could preserve coiled coil function by buffering the effects adventitious inactivating epistatic mutations. Although a comprehensive mechanistic explanation for the role of the coiled coil in L1 activity has yet to be achieved \[[@pgen.1008991.ref028]--[@pgen.1008991.ref034]\], its evolutionary persistence throughout vertebrates \[[@pgen.1008991.ref001]\] attests to its vital role for L1 activity. The fact that the coiled coil is uniquely hypervariable compared to the remainder of ORF1, and that episodes of intense coiled coil amino acid substitutions in primates have been associated with the emergence of novel L1 families imply that such variability is essential to its survival. Murine rodent coiled coils can also be highly variable, but in this case due to changes in length or number of the repeat units (or both) rather than amino acid substitutions \[[@pgen.1008991.ref018]--[@pgen.1008991.ref020], [@pgen.1008991.ref023]\]. Also, whether different versions of the coil can coexist in the same mouse L1 family or mitigate the effect of negative epistatic substitutions \[[@pgen.1008991.ref039]\] has not been addressed. As coiled coils have been identified in at least 10% of all proteins \[[@pgen.1008991.ref041]\], our findings would be relevant to fields beyond L1 retrotransposons. However, two aspects of L1 biology contributed to our detecting intra-family coiled coil variants: Most L1 families generate hundreds or more copies before being superseded by a successor family, and most of these copies are retained in the genome.

Materials and methods {#sec007}
=====================

Plasmid DNA {#sec008}
-----------

pRTC2---This vector is based on the original retrotransposition reporter \[[@pgen.1008991.ref058]\] but it contains the highly active L1.3 \[[@pgen.1008991.ref052]\] sequence kindly provided by Dr. John Moran on the JCC8 vector \[[@pgen.1008991.ref058]\]. We also made other modifications: The pRTC2 backbone was derived from pCEP4 (Invitrogen Life Technologies). We replaced the NruI---SalI-1989 bp fragment by [TCGCGA]{.ul}GAAGTA[GGTACC]{.ul}TAAT[AAGCTT]{.ul}TCAT[GCGGCCGC]{.ul}AGAC[CGATCG]{.ul}AGTCAA[GTCGAC]{.ul}, which contains sites for NruI, KpnI, HindIII, NotI, BsiWI and SalI, underlined, left to right. pRTC2 also differs from the original reporter by the following modifications: the CMV promoter that drove sense transcription of the L1 element was replaced with the SV40 early promoter (flanked by KpnI and HindIII) and the anti-sense G418 gene was relocated from its original position within the L1 3' UTR to down-stream of it, and its SV40 early promoter was replaced with the Rouse sarcoma virus LTR. The annotated sequence of pRTC2 containing the L1.3 L1 sequence (flanked by BsiWI and SalI) is included in [S1 Data](#pgen.1008991.s012){ref-type="supplementary-material"}.

ORF1 mutations were generated by site-directed mutagenesis using QuickChange II (Agilent Technologies) using forward and reverse primer pairs designed with the Agilent Primer Design Program ([www.genomics.agilent.com/primerDesignProgram.jsp0](http://www.genomics.agilent.com/primerDesignProgram.jsp0)) on a vector, MB18-111, described in \[[@pgen.1008991.ref026]\]. This vector contained just the 5'UTR and ORF1 and the mutated ORF1 sequences were isolated as a BsiWI/AgeI fragment, which contained the 5'UTR and encoded all but the C-terminal 10 residues of the 338 amino acid ORF1 sequence. The AgeI site is conserved in 555p and 111p. This fragment was inserted into the corresponding sites of pRTC2_Δ\_BsiWI-AgeI.

ORF1-constructs {#sec009}
---------------

The modern version of human ORF 1, ORF1-111, and the ancestral version, ORF1-555, as well as the mosaic modern-ancestral ORF1 constructs 151, 551, and 511 are shown in [Fig 1](#pgen.1008991.g001){ref-type="fig"} and described in \[[@pgen.1008991.ref026]\]. This paper describes in detail the resuscitation of the ancestral L1Pa5 ORF1 sequence. Basically, we derived a 60% consensus sequence from an alignment of L1Pa5 ORF1 sequences that we had retrieved from the human genome database. We converted to CG those positions in the consensus that corresponded to the positions in the alignment that contained CG and either TG or CA (usually both). We resolved rare ambiguities by comparing the encoded protein to those encoded by L1Pa6 and L1Pa4 consensus sequences. We restored activity of ORF1-151 by sequential steps of PCR site-directed mutagenesis. Generation of the equivalent of ORF1-551 (*i*.*e*., m41 on [Fig 1](#pgen.1008991.g001){ref-type="fig"} and [S3 Fig](#pgen.1008991.s003){ref-type="supplementary-material"}) from ORF1-151 required 25 amino acid changes, 21 of which are located within the coiled-coil domain. The remaining four residues are located in what we designated as the N-terminal domain (NTD), [Fig 1A](#pgen.1008991.g001){ref-type="fig"}. The procedures for constructing the pRTC2 retrotransposition vectors from the intermediate holding vectors described above are given in refs \[[@pgen.1008991.ref026], [@pgen.1008991.ref049]\].

pORF1-FLAG {#sec010}
----------

As described in the Supporting Information of \[[@pgen.1008991.ref049]\], the mammalian expression vectors were constructed with pcDNA3.1(+)-puro (from the Don Ganem laboratory, University of California San Francisco). ORF1-Flag amplicons, containing a 5′ BamH1-Kozak sequence and 3′ EcoRI-FLAG sequence, were generated by PCR with a high-fidelity polymerase from WT or mutant ORF1 pRTC2 templates with the forward primer CGCGGATCCGCAATGGGGAAAAAACAGAAC and reverse primer GCCGGAATTCCTACTTGTCGTCGTCGTCCTTATAATCCATTTTGGCATG. The PCR fragment was inserted into pcDNA3.1(+)-puro. Some mutants were made using WT pORF1-FLAG as a template for site-directed mutagenesis. All mutations were verified by DNA sequencing, and plasmid DNA was purified using the endotoxin-free plasmid DNA purification kit, NucleoBond Xtra Midi EF (Macherey-Nagel). These plasmids were used to compare expression of the various ORF1p constructs.

Retrotransposition assays {#sec011}
-------------------------

The pRTC2 plasmid DNA was amplified in NEB 10-β competent cells (New England Biolabs), and extracted using a midi-prep DNA kit (NucleoBond Xtra Midi EF (MACHERY-NAGEL). HeLa cells (HeLa-JM, kindly provided by John Moran, University of Michigan, Ann Arbor) were plated in 6-well dishes (1x 10^5^ cells in 2 ml) or in 12 well dishes (0.35 X 10^5^ cells in 1 ml) and incubated for 20--24 hours until 60% to 80% confluent. The cells were transfected with 1 μg plasmid DNA and 3 μl Fugene6 Transfection Reagent (Roche) in serum free media for 6-well plates, or 0.5 μg DNA and 1.5 μl Fugene 6 in serum free media for 12-well plates. After 72 hours media was replaced with fresh media containing 400 μg/ml G418 antibiotic (Gibco) and incubations were continued for 8--10 days, replenished as needed with fresh G418-containing media. The cells were washed twice with 1X PBS, fixed with 2% formaldehyde (Mallinkrodt)/0.2% glutaraldehyde (Sigma-Aldrich), washed twice with 1X PBS, and stained with Karyo Max Giemsa Stain (Gibco). The stained cells were sequentially washed with 50% ethanol, 15% ethanol, and then water. The plates were photographed with a Canon EOS Rebel T3i camera body and a Canon Macro LENS EF-S 60 mm 1:2.8 USM lens. The camera was operated with Adobe Photoshop Lightroom 4 software; digital images were quantitated for percent plate coverage by adherent cells, with ImageJ, using the "ColonyArea" plugin \[[@pgen.1008991.ref059]\]. Box plots were generated by KaleidaGraph (v.4.5.2, Synergy Software). At least 4 independent transfections were performed for each assay.

Western Blot analysis {#sec012}
---------------------

Expression assays were carried out essentially as described in the Supporting Information for Cook *et al* \[[@pgen.1008991.ref049]\]. HeLa cells, in six-well plates, were transfected with 1μg of pORF1-Flag constructs using 3μL of FuGENE6 (Promega). After 48 h, the cells were washed with PBS, lysed with 50 mM Tris·Cl pH 7.4, 650 mM NaCl, 1 mM EDTA, 1% Triton X-100, cOmplete EDTA-free protease inhibitor mixture (Roche), 100 μM leupeptin, and sonicated in a Bioruptor (Diagneode) and centrifuged at 17,000 × g for 15 min at 4°. Fifty μg samples of supernatant protein were subjected to denaturing gel electrophoresis, transferred to PVDF membranes using iBlot (Invitrogen), blocked with Superblock T20 buffer (Pierce) and incubated overnight at 4° with mouse anti-FLAG M2 monoclonal antibody (Sigma-Aldrich) and rabbit anti-tubulin (Sigma-Aldrich) that had been diluted in Superblock T20 buffer. After rinsing with 1XTBS/0.05% Tween20, the membranes were subjected to three 10 min washes with the same buffer and incubated for 1.5 h at room temperature with mouse and rabbit anti-horse radish peroxidase antibodies in blocking buffer. After four 10 min washes in 1x TBS/0.05% Tween20, followed by three rinses with 1x TBS the membranes were developed with Pierce Pico-west substrate and exposed to film.

Bioinformatics and sequence analysis {#sec013}
------------------------------------

### ORF1 and coiled coil sequences {#sec014}

L1 sequences corresponding to L1Hs (L1Pa1)--L1Pa7 of sufficient length to include full length ORF1 were identified in repeat masker output files (<http://repeatmasker.org/species/hg.html>) for hg19 (build 37) and hg18 (build 36.1). The corresponding L1Hs and L1Pa2 sequences were retrieved from hg19 using the bedtools getfasta script (2.26.0, <http://quinlanlab.org>), and L1Pa3 --L1Pa7 sequences from hg18 (indexed by formatdb with the--o option) using the blastall program, fastacmd. The sequences were aligned using Muscle \[[@pgen.1008991.ref060]\] as implemented either in SeaView \[[@pgen.1008991.ref061]\] or Biowulf, the NIH HPC system. ORF1 sequences were isolated from these alignments and those with large inserts or deletions were discarded. Sequences corresponding to the coiled coil and carboxy terminal half were located by reference to these regions of L1Pa1 (L1Hs) and our resuscitated ancestral L1Pa5 \[[@pgen.1008991.ref026]\]. The 14-heptad coiled coil was determined by Scorer 2, <http://coiledcoils.chm.bris.ac.uk/Scorer/> \[[@pgen.1008991.ref062]\] numbering the heptads 1--14 starting from the amino terminus and using the amino acid after the end of heptad 14 as the beginning of the carboxy-terminal half of ORF1p. (Note that heptads were numbered in the opposite order in references \[[@pgen.1008991.ref040], [@pgen.1008991.ref045]\]). The coiled coil alignments were refined by reference to the encoded peptide sequences, and CG dinucleotides were restored in the 50% consensus sequences at positions of the alignments that were populated by CG, and TG or CA (usually both). As the L1 families are of different ages, they will have undergone time-dependent decay of their CG dinucleotides \[[@pgen.1008991.ref063]\]. To minimize the confounding effect of this decay on coiled coil amino acid variation, we translated the amino acid positions encoded by CG-affected codons (*i*.*e*., CGN, NCG, NNC•GNN) to the null amino acid character, "O". We then converted amino acids at the corresponding positions of the aligned coiled coil peptides to "O", (subsequently converted to a "-", *i*.*e*., missing data, by downstream processing) prior to principal component and cluster analysis. We refer to such sequences as CG-null and add "\_o\_" to the name of 50% consensus sequences derived from these peptides. [S5 Fig](#pgen.1008991.s005){ref-type="supplementary-material"} shows the 50% consensus peptides for each retrieved cluster (*e*.*g*., 1.7_o, cluster 1 of L1Pa7, see [Fig 3](#pgen.1008991.g003){ref-type="fig"}) which were used for phylogenetic analysis (see next section). These consensus peptides (where X indicates positions which did not reach the 50% threshold) are ordered according to their position on the phylogenetic tree ([Fig 4](#pgen.1008991.g004){ref-type="fig"}). The corresponding consensus peptides with the null amino acid restored to its original value are referred to as CG-restored and have an "\_rt" added to their name (*e*.*g*., 1.7rt). These sequences are also shown in [S5 Fig](#pgen.1008991.s005){ref-type="supplementary-material"} and were used to construct a sequence LOGO of the clusters \[[@pgen.1008991.ref064]\] (<http://weblogo.berkeley.edu>). The LOGO plot in [S6 Fig](#pgen.1008991.s006){ref-type="supplementary-material"} shows that more than one position in every heptad except number 14, was subject to variation. Alignments of ORF1p and ORF2p sequences and those of the coiled coil domains, and clusters thereof (see next section), CG-less translations of the aligned clusters and the C-terminal half of ORF1p are supplied in [S1 Data](#pgen.1008991.s012){ref-type="supplementary-material"}. The Perl script for "CG-less" translation, cg_less_trans.4f.1.pl, its rationale, and a test input file have been deposited to GitHub (<https://github.com/anthony-f/avf_perl>). Routine sequence editing and display were also carried out using EMBOSS as implemented at \<<http://bioinfo.nhri.org.tw/gui/>\>.

Determination of coiled coil sequence space {#sec015}
-------------------------------------------

To determine the coiled coil sequence space of the L1Pa7 --L1Pa1 families we subjected alignments of their coiled coils to two analytical techniques that provide three- or two-dimensional graphical views of sequence relatedness. The first was principal component analysis (PCA) on binary vectors (one-hot) encoding the appearance of amino acids at each position in the sequence in a global alignment of all the coiled coils of all the families in an unbiased manner with no family differences taken into account. One hot encoding assigns to each amino acid a unique 20-bit vector. No specific properties of amino acids were taken into account, but implicit in the one-hot encoding is a set of constraints that enforce the fact that there is only one specific amino acid at every position in any sequence. In particular, PCA does not require a choice of distance or similarity measure between sequences beyond the vector space structure implicit in the one-hot encoding. The python script (furano_v5.py) for PCA using one hot coding and the input alignments have been deposited to GitHub (<https://github.com/nihcompmed/furano>).

We also carried out K-means based cluster analysis on the coiled coil and C-terminal half of each family using the Bios2mds R package \[[@pgen.1008991.ref050]\]. This package uses metric multidimensional scaling (MMDS) to visualize in two dimensions the sequence differences between the aligned coiled coils for each family. Closely related sequences appear as clusters and this package provides various functions for additional analysis such as sequence retrieval from each cluster. We used RaXml \[[@pgen.1008991.ref056]\] running on the NIH High Performance Cluster (HPC) system to carry out phylogenetic analyses on the 50% consensus sequences of these clusters and visualized the trees with Dendroscope 3 \[[@pgen.1008991.ref065]\]. We also used the usearch V11 suite to probe the ORF1 coiled coils of L1Pa1, L1pa2, and their immediate ancestor, cluster 1 of L1pa3 (cL1.3) for emerging sub-clusters by using its cluster_fast command with an -id (identity) parameter set to 1.00\[[@pgen.1008991.ref057]\]. This would recover coiled coil clusters that are minimally divergent from their consensus coiled coils.

Supporting information {#sec016}
======================

###### ORF1p variant expression in HeLa cells.

Fifty μg samples of extracts from HeLa cells expressing C-terminally FLAG-tagged ORF1p of the indicated constructs were subject to denaturing gel electrophoresis and Western blotting with anti-Flag and anti-tubulin antibodies as described in the Materials and Methods / **Western Blot Analysis**. The \* indicates ORF1p constructs that were active for retrotransposition.

(PDF)

###### 

Click here for additional data file.

###### Retrotransposition assays of ORF1p variants.

These assays are in addition to those shown in [Fig 1C](#pgen.1008991.g001){ref-type="fig"} carried out as described in Materials and Methods / **Retrotransposition assays**. To reduce the size of the file, stained cell foci are only shown for the retrotranspositions in panel A.

(PDF)

###### 

Click here for additional data file.

###### ORF1p variants.

The full version of [Fig 1B](#pgen.1008991.g001){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### C-term clusters.

Alignments of the C-terminal half (see [Fig 1A](#pgen.1008991.g001){ref-type="fig"}) of L1Pa7 --L1Pa3 were analyzed using the Bios2mds R package \[[@pgen.1008991.ref050]\] as described in the Materials and Methods.

(PDF)

###### 

Click here for additional data file.

###### Alignment cluster consensus sequences.

The peptides of the indicated cluster consensus without the CG-affected amino acids (CG-null), indicated by \_o, vs. the consensus sequence with the amino acids encoded by CG-affected sites restored, rt.

(PDF)

###### 

Click here for additional data file.

###### LOGO plot.

LOGO plot of 50% consensus coiled coil peptide sequences, with CG positions restored, labeled rt in [S5 Fig](#pgen.1008991.s005){ref-type="supplementary-material"}. Arrow heads indicate position of the ancestral amino acids that are negatively epistatic in the modern context.

(PDF)

###### 

Click here for additional data file.

###### L1Pa1_cc_align.

Alignment of L1Pa1 coiled coil peptide sequences vs the 50% consensus sequence of the CG-null L1Pa1 coiled coil.

(PDF)

###### 

Click here for additional data file.

###### L1Pa2_cc_align.

Alignment of L1Pa2 coiled coil peptide sequences vs the 50% consensus sequence of the CG-null L1Pa2 coiled coil.

(PDF)

###### 

Click here for additional data file.

###### L1Pa2_ccF134_align.

Alignment of L1Pa2 CG-null coiled coil peptide sequences that have an F at position 134 vs the 50% consensus sequence of L1Pa2.

(PDF)

###### 

Click here for additional data file.

###### L1Pa2_cc_nonF134_align.

Alignment of L1Pa2 CG-null coiled coil peptide sequences that lack F at position 134 vs the 50% consensus sequence of L1Pa2.

(PDF)

###### 

Click here for additional data file.

###### cL1.3_cc_align.

Alignment of the L1Pa3 cluster1 coiled coil peptide sequences vs the 50% consensus sequence of the CG-null cL1.3 coiled coil and the 50% consensus sequences of the L1Pa1 and L1pa2 coiled coils.

(PDF)

###### 

Click here for additional data file.

###### Compendium of all of the ORF1 and ORF2 sequences and their provenance used in this paper, an explanatory README file, and the annotated sequence of the retrotransposition vector, pRTC2L1.3.txt (zipped file).

(ZIP)

###### 

Click here for additional data file.

This work utilized the computational resources of the NIH HPC Biowulf cluster. (<http://hpc.nih.gov>).

10.1371/journal.pgen.1008991.r001
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Dear Dr Furano,

Thank you very much for submitting your Research Article entitled \'CRYPTIC GENETIC VARIATION ENHANCES PRIMATE L1 RETROTRANSPOSON SURVIVAL BY ENLARGING THE FUNCTIONAL COILED COIL SEQUENCE SPACE OF ORF1p\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

In particular, Reviewer \#1 expresses substantial criticism about the presentation and writing quality (notably the excessive use of jargon). These issues would require thorough revisions to the text and narrative/rationale for the experiments in order to make the paper more broadly accessible outside of the L1 community.      

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Cédric Feschotte

Associate Editor

PLOS Genetics

Bret Payseur
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Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Furano and colleagues present an extension of previous work from their lab (Nabuan Naufer, et al 2016) surrounding the fascinating question of what drove the rapid evolution of L1 ORF1p in early primate evolution. In their previous work, the group observed loss of retrotransposition activity from a chimeric ORF1 comprised of segments from modern (L1HS/PA1) and ancient (PA5) L1s and nicely demonstrated that this loss of activity in the chimera derived from a comprised rate of ORF1p trimerization. In the present manuscript, the group presents a more thorough mutagenesis of ORF1 guided by the changes that occurred between the PA5 and PA1 consensuses. The authors create numerous chimeras and targeted mutants and measure the retrotransposition activity of each. Generally, the data support that there are mutations that have no measurable effect on in vitro retrotransposition, mutations that have moderate effect, mutations that inactivate, and mutations for which their effect of function differs based on the sequence of the rest of ORF1. The logic for why the authors chose the specific mutations they present and any deeper interpretations of interactions amongst mutations is lost in a dense and confusing narrative and presentation of the data. The subsequent analyses of the sequence space of L1 subfamilies was unclearly motivated and hard to follow, and the conclusions made from these data overreached. Overall, the manuscript's density, jargon, and lack of narrative make it a tough fit for PLOS Genetics. With a clearer motivation of each experiment and a tempering of conclusions, this paper would be a reasonable addition to the literature in a more specialized journal.

Major Points:

1\) The motivation for carrying out each experiment is unstated, and the results section is extremely abrupt in its opening. A clear presentation of the reason and rationale for each experiment would be very helpful.

2\) The authors seem to confound the accepted use of several distinct terms as used in the protein evolution field. First, it has been widely shown in many types of systems that natural proteins tend to be tolerant of most mutations (robustness) but also capable of functional change upon mutation at specific positions which comprise a minority of the sequence (adaptability or evolvability). This robust state of most proteins may result in the accumulation of mutations which are neutral in the context of the present fitness function, but upon some change (environmental, sequence change elsewhere, etc) become advantageous -- these now adaptive changes were cryptic. The relevance of the concept of cryptic variation to the manuscript is unclear, and the above terms are oft used inappropriately. For example, (line 134) "Genetic robustness would be permissive to the accumulation of cryptic genetic changes - termed "evolvability"...". There are many definitions of evolvability, but evolvability and cryptic variation are not synonymous. The relevance of this concept should be much more clearly elaborated.

Further, it seems that (ln 225) "relative indifference of L1 retrotransposition activity to extensive ORF1p coiled coil amino acid substitutions" and the (ln 228) "expansion of the functional coiled coil sequence space" are the same. Protein robustness is the expansion of functional sequence space via "indifference" to mutation.

To clarify these statements, it would be useful to reference more of the extensive literature on protein robustness and evolvability and provide a deeper discussion of how these topics relate to the data presented.

3\) The finding of context dependence of mutations (epistasis) within ORF1p is not surprising; it likely exists in every protein. It could be interesting to interpret the observed epistasis in the context of the CC structure to try to find mechanistic explanation of the observed effects. Indeed, the manuscript would benefit from a more thorough discussion of how these findings should be interpreted in the context of the ORF1p structure (Khazina, et al. NSMB 2011), and how the present manuscript differs from the mutagenesis data presented in that paper.

Minor Points:

1\) The figure are generally very dense and hard for me to parse. I suggest minimizing the number of colors and sequences to highlight the most important points (eg, a 25 seq alignment (fig 1B) and \>20 colors (fig 4))

2\) The construct names are non-intuitive and make any comparison of sequence differences vs activity difference tough. (fig 1)

3\) If the conclusion of the PCA is that ORF1 is robust, it seems that you don't need PCA to observe and quantify variation in this sequence. (ln 155)

4\) The observation that "the paired active and inactive variants share the same sequence space" does not demonstrate epistasis (ln 156); it is well-known that single mutations can completely inactivate with little dependence on the rest of the sequence (for example, a highly thermodynamically destabilizing mutation).

5\) The title and introduction needs much less jargon; specifically, the title borrow complex jargon from several fields, making it hard to understand for specialists from many fields.

6\) In the discussion, cis preference is mentioned to support why hybrid trimer formation would not be the driver of having coexisting versions of coil coiled domains within a LINE1 family. Cis preference is known for ORF2p binding to LINE1 mRNA, but this is not necessarily the case for ORF1p?

Reviewer \#2: This work is from a group that in the past has published seminal work on the domain functions of L1 ORF1p and on the evolution of LINE-1 families in both human and non-human genomes. As noted by the authors, variations in the ORF1p coiled-coil domain have previously been interpreted to adaptive evolution by the L1. In this study, Furano and group, expand significantly on the earlier studies to explore in detail the evolutionary dynamics of the coiled-coil domain of ORF1p, relating this to retrotransposition function in an established cell culture reporter assay, and demonstrating a couple of genetic phenomena along the way.

Nevertheless, this study provides no insights into the mechanism effects of the various mutations and expansions of the coiled coil domain of ORF1p, beyond the cell culture assay \-- and this assay is a final readout of cumulative mechanisms of retrotransposition and does not itself provide mechanistic insights. Possible experiments might explore effects on chaperone activity, trimerization, or subcellular localization using immunomicroscopy. The authors hint at such experiments in the discussion but do not attempt them. Furthermore, as cited, this group has also previously reported that extensive amino acid substitutions have occurred during evolution of the L1Pa7-L1Pa3 families.

The question is, therefore, is the present detailed study of the ORF1 coiled coil of sufficient interest and scope for the readers of PLoS Genetics. While perhaps somewhat debatable, I would say yes. Using multiple and mutually supporting computational approaches, the study teases out the evolutionary dynamics of an essential cis protein for retrotransposition of the LINE-1, which comprises at least 17 percent of the human genome. The authors clearly show epistasis (eg., the effect of I77L) and genetic robustness of the coiled coil domain. They demonstrate in considerable detail the varied evolutionary history of the CC domain of ORF1, distinct from that of the c-terminal domain of ORF1p and of ORF2p. Phylogenetic and PCA analyses also allowed the authors to identify distinct coiled-coil clusters and to reveal their persistence through L1 family evolution.

There are a number points that warrant further clarification/elaboration prior to publication:

On line 101 the previously described (ref. 26) \"resuscitated\" L1Pa5 ORF1p is noted. A sentence or two on how the resuscitation was originally engineered would help reader understanding.

On line 114 and in Fig. 1, it is stated that ORF1 proteins are expressed at about the same extent in HeLa cells. This is clearly not the case - there would appear to be up to a 3-fold difference, especially obvious in the case of L107F. Properly, band intensities of non-saturating Western blot exposures should be measured, with ORF1p level presented as a ration of tubulin expression. Accurate measurements of expression levels (and also transfection efficiencies) are important in assessing retrotransposition assay results.

The antibiotic-based retrotransposition assay used here has traditionally been run by first selecting cells on hygromycin for transfection, and then on G418 to select for retrotransposition. The readout is then number of retrotransposition events/number of transfected cells, which controls for variations in transfection efficiencies. This paper failed to select on hygromycin, therefore a discussion of this fact and any possible bias should be included.

Clarity of the data would be increased by reproducing the retrotransposition frequency data in an additional column for each of the constructs described in Fig. 1B.

Line 181: I failed to find Supporting Data/orf1_FL/l1pa5. Is reference being made to a portion of a different file?

Line 195: I was confused by reference to the \"circled node\" in Fig. 4. Do you mean the colored circles?

Line 262: the cis-preference model is somewhat misstated, and the sentence should better read: \"\... whereby retrotransposition-competent L1 proteins bind their encoding transcript\". The early experiments on cis-preference indicated that cis-binding was a component of successful retrotransposition, not that L1 proteins could not bind in trans to non-retrotransposition intermediates.

Line 265. It is stated: \"Furthermore, there is evidence that translation can be sequestered in subcellular compartments or translation factories (eg. 49)\". The relevance of this specifically to the L1 is unclear.

Methods, line 309. A number of modifications were made to the retrotransposition vector pRTC2, including moving the reporter cassette and swapping in new promoters. Explanations of why these changes were made would be of interest to members of the field.

Reviewer \#3: In the manuscript entitle "Cryptic genetic variation enhances primate L1 retrotransposon survival by enlarging the functional coiled coil sequence space of ORF1p" the authors present an original analysis of the human LINE-1 ORF1p coiled coil domain. They used bioinformatic tools to study the expansion of the sequence space of the coiled-coil functional domain.

This manuscript is very well written. The work presented here is of great interest in the field retrotransposon biology, it contributes to our understanding on the variability of the N terminal domain of ORF1p to maintain its activity. It would also contribute to a general understanding on coiled coil domain variability of any protein.

One remaining question could be addressed in more detail in the discussion. This concern line 250 to 255 page 9. Based on the results, the authors suggest that different coiled coil sequences amplified concurrently through several subfamilies. Then, how to explain the presence of several coiled coil domains shared in different subfamilies, since these subfamilies, based on ORF2 phylogeny, appeared sequentially in a unique linear history? It would imply that the coiled coil domain of ORF1p (or the entire ORF1p sequence) can be exchanged between L1 subfamilies. It could also suggest, less likely, convergent mutations of the coiled coil sequence in different subfamilies.
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Line 254, Figs 4 and 5 instead of 5 and 6
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Line 181, Supporting Data/orf1_FL was not provided
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